Related Experiment Video

Updated: Feb 28, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Treating ER+ Breast Cancer with CDK4/6 Inhibitors

    Cancer Discovery
    |June 20, 2017
    PubMed

    Insights

    CDK4/6 inhibitors combined with endocrine therapy are effective for advanced ER-positive breast cancer. This combination improves progression-free survival and may overcome resistance to hormone treatments.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Advanced ER-positive breast cancer is a significant clinical challenge.
    • Endocrine therapy is a standard treatment but acquired resistance can limit efficacy.

    Purpose of the Study:

    • To evaluate the efficacy of CDK4/6 inhibitors in combination with endocrine therapy for advanced ER-positive breast cancer.
    • To assess the impact of this combination on progression-free survival and acquired resistance.

    Main Methods:

    • Analysis of data from MONARCH2, PALOMA-1, and TREnd clinical trials.
    • Inclusion of patients with advanced ER-positive breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

    Main Results:

    • Strong evidence supports the use of CDK4/6 inhibitors with endocrine therapy.
    • The combination significantly improves progression-free survival.
    • Potential to reverse acquired resistance to hormone treatment.

    Conclusions:

    • CDK4/6 inhibitors represent a valuable addition to endocrine therapy for advanced ER-positive breast cancer.
    • This therapeutic strategy offers improved outcomes and overcomes treatment resistance.

    More Related Videos

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

    Published on: October 26, 2015

    11.9K
    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

    Published on: April 26, 2024

    4.0K

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    6.7K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.2K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.2K
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.1K